Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Publisher Name :
Date: 22-Jan-2013
No. of pages: 60

GBI Research, the leading business intelligence provider, has released its latest research, "Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share", which provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.

Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in the forecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol (fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that the generic sector in the global statins market will grow significantly in the future and will pose tough competition to new molecules.

Scope


  • Data and analysis on the statins market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.

  • Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018.

  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population.

  • Share of generics in the global statins market.

  • Key drivers and restraints that have had a significant impact on the global statins market.

  • The competitive landscape of the global statins market, including top companies benchmarking. The key companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis.

  • Key M&A activities and licensing agreements that took place in the statins market.


Reasons to buy


  • Align their product portfolio to the markets with high growth potential

  • Build effective strategies to launch their pipeline products by identifying potential geographies

  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

  • Develop key strategic initiatives by studying the key strategies of top competitors

  • Devise more tailored country-specific strategies through the understanding of key drivers and barriers and the market potential of each indication for different territories

  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth

  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious

Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Statins Market to 2018 - Introduction 8

3 Statins Market to 2018 - Global Statins Market 9
3.1 Introduction 9
3.2 Global Market Forecast 10
3.2.1 Branded and Generic Market Share 12
3.3 Annual Cost of Treatment 13
3.4 Treatment Usage Patterns 14
3.4.1 Disease Population 15
3.4.2 Treatment Seeking Population 15
3.4.3 Diagnosed Population 15
3.4.4 Prescription Population 15
3.5 Drivers and Restraints to the Statins Market 16
3.5.1 Drivers to the Statins Market 16
3.5.2 Restraints to the Statins Market 17
3.6 Major Marketed Products 19
3.6.1 Crestor (rosuvastatin calcium) 19
3.6.2 Lipitor (atorvastatin calcium) 20
3.6.3 Vytorin (ezetimibe/simvastatin) 21
3.6.4 Zocor (simvastatin) 22
3.6.5 Livalo (pitavastatin calcium) 22
3.6.6 Lescol XL (fluvastatin sodium) 23
3.6.7 Pravachol (pravastatin sodium) 24

4 Statins Market to 2018 - Statins Market in the US 25
4.1 Market 25
4.2 Annual Cost of Therapy (ACT) 27
4.3 Treatment Usage Pattern 28
4.3.1 Diseased Population 29
4.3.2 Treatment Seeking Population 29
4.3.3 Diagnosed Population 29
4.3.4 Patients on Statins Therapy 29

5 Statins Market to 2018 - Statins Market in the Top Five Countries of Europe 30
5.1 Market 30
5.2 Annual Cost of Therapy 33
5.3 Treatment Usage Pattern 34
5.3.1 Diseased Population 35
5.3.2 Treatment Seeking Population 35
5.3.3 Diagnosed Population 35
5.3.4 Patients on Statins Therapy 35

6 Statins Market to 2018 - Statins Market in Japan 36
6.1 Market 36
6.2 Annual Cost of Therapy 38
6.3 Treatment Usage Pattern 40
6.3.1 Diseased Population 41
6.3.2 Treatment Seeking Population 41
6.3.3 Diagnosed Population 41
6.3.4 Patients on Statins Therapy 41

7 Statins Market to 2018 - Product Pipeline Anlaysis 42
7.1 Introduction 42
7.2 Pipeline Analysis 42

8 Statins Market to 2018 - Competitive Landscape 43
8.1 Pfizer Inc. 44
8.1.1 Company Overview 44
8.1.2 SWOT Analysis 44
8.2 AstraZeneca PLC (AstraZeneca) 45
8.2.1 Company Overview 45
8.2.2 SWOT Analysis 45
8.3 Merck & Co Inc 46
8.3.1 Company Overview 46
8.3.2 SWOT Analysis 46
8.4 Novartis AG (Novartis) 47
8.4.1 Company Overview 47
8.4.2 SWOT Analysis 47

9 Statins Market to 2018 - Strategic Consolidation 48
9.1 Merger and Acquisition (M&A) Deals 48
9.2 Licensing Deals 49
9.2.1 Licensing Deals by Geography 49
9.3 Co-development Deals 51

10 Statins Market to 2018 - Appendix 52
10.1 Market Definitions 52
10.2 Abbreviations 52
10.3 Bibliography 55
10.4 Research Methodology 56
10.4.1 Coverage 56
10.4.2 Secondary Research 56
10.4.3 Primary Research 57
10.4.4 Therapeutic Landscape 57
10.4.5 Geographical Landscape 60
10.4.6 Pipeline Analysis 60
10.4.7 Competitive Landscape 60
10.5 Expert Panel Validation 60
10.6 Contact Us 60
10.7 Disclaimer 60

 List of Tables

Table 1: Statins Market, Global, Revenue ($bn), 2004-2011 10
Table 2: Statins Market, Global, Revenue Forecast ($bn), 2011 -2018 10
Table 3: Statins Market, Global, ACT ($), 2004-2011 13
Table 4: Statins Market, Global, ACT ($), 2011-2018 13
Table 5: Statins Market, Global, Treatment Usage Patterns (million), 2004-2011 14
Table 6: Statins Market, Global, Treatment Usage Patterns (million), 2011-2018 14
Table 7: Statins Market, the US, Revenue ($bn), 2004-2011 25
Table 8: Statins Market, the US, Revenue Forecast ($bn), 2011-2018 25
Table 9: Statins Market, the US, ACT ($), 2004-2011 27
Table 10: Statins Market, the US, ACT ($), 2011-2018 27
Table 11: Statins Market, the US, Treatment Usage Pattern (million), 2004-2011 28
Table 12: Statins Market, the US, Treatment Usage Pattern (million), 2011-2018 28
Table 13: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 31
Table 14: Statins Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 31
Table 15: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2011 33
Table 16: Statins Market, Top Five Countries of Europe, ACT ($), 2011-2018 33
Table 17: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2011 34
Table 18: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011-2018 34
Table 19: Statins Market, Japan, Revenue ($bn), 2004-2011 36
Table 20: Statins Market, Japan, Revenue Forecast ($bn), 2011-2018 36
Table 21: Statins Market, Japan, ACT ($), 2004-2011 38
Table 22: Statins Market, Japan, ACT ($), 2011-2018 38
Table 23: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2011 40
Table 24: Statins Market, Japan, Treatment Usage Pattern (million), 2011-2018 40
Table 25: Statins Market, Global, Product Pipeline, 2012 42
Table 26: Statins Market, M&A Deals ($m), 2008-2011 48
Table 27: Statins Market, Licensing Deals, 2005-2011 49
Table 28: Statins Market, Co-Development Deals, 2005-2008 51

 List of Figures

Figure 1: Statins Market, Global, Revenue ($bn), 2004-2018 10
Figure 2: Statins Market, Global, Generic and Branded Market Share (%), 2011 and 2018 12
Figure 3: Statins Market, Global, ACT ($), 2004-2018 13
Figure 4: Statins Market, Global, Treatment Usage Patterns (million), 2004-2018 14
Figure 5: Statins Market, Global, Drivers and Barriers, 2011 16
Figure 6: Statins Market, the US, Revenue ($bn), 2004 -2018 25
Figure 7: Statins Market, the US, ACT ($), 2004-2018 27
Figure 8: Statins Market, the US, Treatment Usage Pattern (million), 2004-2018 28
Figure 9: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018 31
Figure 10: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2018 33
Figure 11: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2018 34
Figure 12: Statins Market, Japan, Revenue ($bn), 2004-2018 36
Figure 13: Statins Market, Japan, ACT ($), 2004-2018 38
Figure 14: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2018 40
Figure 15: Statins Market, Global, Top Companies' Market Share (%), 2011 43
Figure 16: Statins Market, Pfizer Inc., SWOT Analysis, 2011 44
Figure 17: Statins Market, AstraZeneca, SWOT Analysis, 2011 45
Figure 18: Statins Market, Merck & Co. Inc., SWOT Analysis, 2011 46
Figure 19: Statins Market, Novartis, SWOT Analysis, 2011 47
Figure 20: Statins Market, Strategic Consolidation, 2005-2011 48
Figure 21: GBI Research Market Forecasting Model 59

  • China Commercial Vehicle Industry
    Commercial vehicle are usually large trucks, buses or vans used to transport people,  goods and material. China is one of the nations that contributes to over 50% of commercial vehicle production. The industry has grown in leaps and bounds over the couple of years. Even though the growth rates aren’t as impressive as two years [...]
  • The Prospective Market of Drug Eluting Stents
    Drug Eluting Stents are the recent development that’s are now being used frequently for curing narrowed coronary arteries. These stents help to keep the artery open and supply drugs at regular intervals preventing any further obstruction. The stents are usually small scaffolds of wire and are placed in the artery. This has been a welcome [...]
  • Anaesthesia Machine Industry is Flourishing due to an Extensive Customer Base with Therapeutic Needs
    The Anaesthesia Machine Industry comprises of the manufacturers and users of Anaesthesia Machines which are basically workstations or units that assist a person to administer Anaesthesia on the other. It includes plug & play Anaesthesia delivery units (ADUs). The industry also comprises of the various accessories like monitors and information systems and support services involved [...]
  • The Need for an Electric Cars Boosts The Lithium Sulfate Market
    Lithium is a highly demanded material. The popularity of this metal is primarily due to the characteristics of this metal and its compounds. Some of the characteristics of this material are that it has the highest electrochemical potential of all metals, a very high co-efficient of thermal expansion, acting as a viscosity modifier in melts, [...]
  • Tire Roller Industry
    Tire roller is one of the most popular equipment used in the construction industry. A tire roller offers multiple services from building highways, industrial sites, binder courses, wear courses and many more. Tire rollers come with different features like easy adjustment of tyres, flexible ballast, oscillating tires, etc. that facilitates in doing a particular work. [...]
    • The Oil Drilling Rig Industry
    • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…

    • HER2-Negative Breast Cancer’s Therapeutic Market
    • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can …

    • The Market of Plate Heat Exchanger
    • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitat…

    • The Industry of Binding Machines
    • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the bind…

    • The Boom In Women Infertility Market
    • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution
    Published: 18-May-2012        Price: US 3500 Onwards        Pages: 129
    Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution Summary GBI Research, the leading business intelligence provider, has released its latest research “Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution”. The report provides in-depth analysis ......
  • Cardiovascular Disease - Pipeline Review, H2 2012
    Published: 26-Dec-2012        Price: US 2000 Onwards        Pages: 470
    Cardiovascular Disease - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Cardiovascular Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular ......
  • Atherosclerosis - Pipeline Review, H1 2013
    Published: 28-Feb-2013        Price: US 2000 Onwards        Pages: 243
    Atherosclerosis - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Atherosclerosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Atherosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atherosclerosis. Atherosclerosis - Pipeline Review, Half Yea......
  • Global Cardiovascular Drugs Market 2012-2016
    Published: 22-Mar-2013        Price: US 3000 Onwards        Pages: 110
    TechNavio''s analysts forecast the Global Cardiovascular Drugs market to decline at a CAGR of 10.47 percent over the period 2012-2016. One of the key factors affecting market growth is the over-dependency of the market on the US. The Global Cardiovascular Drugs market has also been witnessing an increase in R&D activities. However, the increase in healthcare expenditure could be one of the factors that will contribute to the growth of this market. TechNavio''s report, the Global Cardiovas......
  • Cardiovascular Disease: Recent Drug Advances and Impending Risks
    Published: 19-Jun-2013        Price: US 1495 Onwards        Pages: 108
    There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace. Successful players will, necessarily, need to cannibalise their existing cardiovascular franchises in order to limit the impact of generic erosion when their patents expire, whilst ......
  • PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
    Published: 30-Jun-2013        Price: US 10995 Onwards        Pages: 260
    The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generi......
  • PharmaPoint: Chronic Heart Failure - France Drug Forecast and Market Analysis to 2022
    Published: 30-Jun-2013        Price: US 4995 Onwards        Pages: 103
    PharmaPoint: Chronic Heart Failure - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Heart Failure - France Drug Forecast and Market Analysis to 2022". The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major glob......
  • PharmaPoint: Chronic Heart Failure - Germany Drug Forecast and Market Analysis to 2022
    Published: 30-Jun-2013        Price: US 4995 Onwards        Pages: 101
    PharmaPoint: Chronic Heart Failure - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Heart Failure - Germany Drug Forecast and Market Analysis to 2022". The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major gl......
  • PharmaPoint: Chronic Heart Failure - Italy Drug Forecast and Market Analysis to 2022
    Published: 30-Jun-2013        Price: US 4995 Onwards        Pages: 100
    PharmaPoint: Chronic Heart Failure - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Heart Failure - Italy Drug Forecast and Market Analysis to 2022". The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs